Antiflankens and a New Antiviral

The new anti funnels and then one new antiviral that I'm very that I actually am very excited about. The first is a novel or in oral glycan synthesis inhibitor, it recently got FDA approved at a dose of 300 milligrams twice a day for one day for full of vaginal candidiasis. It's nice because it can be administered weekly so it has this really long half life. And the solstice trial was finally published in CID which is looking at morebivir for refractory resistant CMV. This drug prevents CMV from replicating but it treats GAN cycle of your resistant isolates based on its different mechanism of action.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app